Daiichi Sankyo Company Limited (4568)

Daiichi Sankyo Company Limited (4568) - Sriram Rathi at Centrum Broking

The synergy with Daiichi and exponential growth in the Indian formulations market will be the key reason for this," said Sriram Rathi, analyst with Centrum Broking. 

Daiichi Sankyo Company Limited (4568) - Tracy Staton at Fierce Pharma

Daiichi Sankyo joins the list of branded drugmakers looking to diversify into the generics business in Japan. The difference is that Japan is Daiichi's home market. . Like other drugmakers who've recently announced their intentions to build up their generics businesses in that country, Daiichi knows that demand for copycat meds is likely to grow enormously as the Japanese government turns to the knockoffs as a way to hold down healthcare costs. 

Daiichi Sankyo Company Limited (4568) - Kenji Masuzoe at Deutsche Bank

Forecasts for full year sales and operating profit were kept at 960 billion yen and 96 billion yen respectively A strengthening of the rupee against the dollar may lead to a gain on currency derivatives at its 64 percent owned Ranbaxy unit, Daiichi Sankyo said, helping to buffer slower sales growth of brand name medicines The shares dropped the most in more than eight months after the Tokyo based company said promotion fees from its newest product, the blood thinner Effient, contributed about 01 percent of revenue last quarter "Effient isn't selling," said Kenji Masuzoe , a pharmaceuticals analyst at Deutsche Bank AG in Tokyo, in a telephone interview today 

Daiichi Sankyo Company Limited (4568) - Sarabjit Kour Nangra at Angel Broking

Ranbaxy said after the market close on Thursday it had received a letter dated 21 December about violations at its Ohm unit's liquid manufacturing facility in New York Stock markets were closed on Friday and Monday, and in the first market reaction to the news, Ranbaxy shares fell as much as 4 per cent At 0600 GMT the shares were down 1 per cent at Rs 51480 in a Mumbai market up 01 percent "It will have some impact on the stock but not a devastating impact," said Sarabjit Kour Nangra, a pharmaceuticals analyst with Mumbai's Angel Broking 

Daiichi Sankyo Company Limited (4568) - Abhishek Singhal at Macquarie

That compares with a year earlier loss of 3.95 billion rupees, and analysts' projection of a 428.5 million rupee profit, based on the median of 12 estimates compiled by Bloomberg in the past four weeks. Demand in India, South Africa and other emerging markets, responsible for 62 percent of revenue, helped Ranbaxy offset a sales decline in the U.S., the world's biggest pharmaceutical market. Profitability also improved at the company, whose shares climbed the most in a month after the results. "The operating margin is the biggest positive surprise," said Abhishek Singhal , an analyst at Macquarie Group Ltd in Mumbai with an "underperform" rating on Ranbaxy, said by telephone. "It has to be seen whether this can be sustained in the coming quarters." . 

Daiichi Sankyo Company Limited (4568) - Sarabjit Kour Nangra at Angel Broking

While Ranbaxy, Strides and Natco Pharma rose 5 19 per cent, Cipla closed 0.5 per cent lower after rising as much as 3.3 per cent in the day. "It is a sentimental impact," said Sarabjit Kour Nangra, vice president research, pharmaceuticals, at Angel Broking. "This is unlikely to sway too much the profitability picture of these companies." . A dealer, declining to be named, said the shares were unlikely to stay up for more than a couple of days. 

Daiichi Sankyo Company Limited (4568) - Hidemaru Yamaguchi at Citigroup Global

Daiichi's stance is very clear—whenever Ranbaxy's result is announced, it will be incorporated in the earnings three months later. So, if we forget about Ranbaxy's foreign exchange, Daiichi's result is in line," said Hidemaru Yamaguchi, an analyst with investment bank Nikko Citigroup Ltd in Japan.  

Daiichi Sankyo Company Limited (4568) - Jim Edwards at BNET

Ranbaxy continued its mission to embarrass itself as much as possible by issuing a recall for a skin infection treatment just as it expects a final meeting with the FDA on the drugs the agency banned Ranbaxy from selling in the U.S. , Bloomberg reported. The recalled drug is 40 milligram Sotret isotretinoin capsules. Ranbaxy told Bloomberg the recall was "normal." 

Daiichi Sankyo Company Limited (4568) - Hidemaru Yamaguchi at Citigroup Global

"Daiichi Sankyo faces several hurdles for the near term, but it's the only major (Japanese) drugmaker that can outgrow (over the long run)," said Nikko Citigroup analyst Hidemaru Yamaguchi.  

Daiichi Sankyo Company Limited (4568) - Yasuhiro Nakazawa at Mitsubishi UFJ

LONG TERM PICK ME UP Daiichi Sankyo last month replaced Ranbaxy chairman and CEO Malvinder Singh, a member of the Indian firm's founding family, with its own executive and a Ranbaxy chief operating officer in a bid to resolve problems at the unit, which has been hit by a partial U.S ban over alleged data falsification. [ID:nBOM425967] "Daiichi Sankyo's direct involvement in Ranbaxy's management and talks with the FDA should help progress efforts to resolve Ranbaxy's problems with the FDA, which have lingered since 2006," said Mitsubishi UFJ Securities analyst Yasuhiro Nakazawa, referring to the U.S. Food and Drug Administration. KBC Securities analyst Philip Hall said the reshuffle was positive as there had been issues over Ranbaxy's quality control. "We're only too aware that holding the stock has been an unpleasant experience over the past year, but we are of the view that the worst is over," Hall wrote in a report.